AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06254209 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanicals extracts
Description: Powder included in capsules for daily administration
Study NCT06254209 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin included in capsules for daily administration
Study NCT05935774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05935774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05935774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05935774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05935774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05935774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05935774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabedersen (OT-101)
Description: Given IV
Study NCT06541782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic CAT-based Intervention
Description: The experimental dyadic CAT-based intervention will promote mutual sensorimotor play, pretend play, songs, and games among the mother-child dyads while encouraging flexibility, creativity, and enjoyment. This intervention will involve eight weekly 45-minute sessions in the families' homes and will be conducted by trained creative art therapists. The dyadic CAT-based intervention will follow a manualized protocol presenting the goals, principles, and proposed activities for the intervention sessions. It will provide instructions for maintaining intervention fidelity, while allowing flexibility to tailor the meetings to each dyad's strengths and needs. The dyadic CAT-based intervention meetings will be recorded using video camera.
Study NCT06541782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Educational Parent Counseling
Description: This intervention will involve only mothers and will be conducted by trained parent counselors with experience in working with IDD. This intervention will involve eight weekly 45-minute sessions performed online via Zoom. The psycho-educational parent counseling will follow a protocol presenting the goals, principles, and central issues in parenting a child with IDD to improve the parent-child relationship and address concerns and difficulties related to the child's diagnosis, development, and behavior. It will provide general instructions for maintaining study validity and replication, while allowing flexibility to tailor the intervention to each family's needs.
Study NCT06161532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered IV at 1200 mg on day 1 each 21-day cycle.
Study NCT04941755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days
Study NCT06240845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-level laser therapy
Description: This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
Study NCT06240845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
Study NCT05024188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Agarose Capsules
Description: Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
Study NCT05219409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2)
Study NCT05219409 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Professional CGM
Description: The sensor records the patient's glucose readings every 15 minutes for up to 14 days.
Study NCT05219409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Professional CGM
Description: The sensor records the patient's glucose readings every 15 minutes for up to 14 days.
Study NCT04748094 — intervention group
Intervention type: DEVICE
Intervention: Compression belt
Description: The abdominal belt is fastened around the lower abdomen and inflated (like an inner tube) to apply pressure to the belly and reduce the motion associated with respiration (breathing)
Study NCT04748094 — intervention group
Intervention type: OTHER
Intervention: Visual Guided Breath-hold
Description: A small tracer will be place on the lower abdomen that will feedback to a computer screen that will have graphics to show you if the participant is in breath-hold or not.
Study NCT06189183 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Hypofractionation Radiotherapy
Description: Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
Study NCT04809428 — intervention group
Intervention type: PROCEDURE
Intervention: vNOTES salpingectomy
Description: Surgical removal of both salpinx by vNOTES with using a 3-cm of posterior colpotomy and either glove port or Gel point V path. Colpotomy will be closed with using 2.0 rapid vicryl.
Study NCT04809428 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic salpingectomy
Description: Surgical removal of both salpinx by conventional laparoscopy in a standardised fashion: with using one 10-mm umbilical and two 5-mm lateral ports.
Study NCT06460428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive video usage
Description: The implementation of the research was carried out in two stages. In the first stage, interactive videos were created, in the second stage, the experimental group was trained with interactive videos, and no intervention was made to the control group.
Study NCT04727346 — intervention group
Intervention type: RADIATION
Intervention: CBCT
Description: Cone Beam Computed Tomography
Study NCT04727346 — intervention group
Intervention type: PROCEDURE
Intervention: DISE
Description: Drug Induced Sleep Endoscopy
Study NCT05603078 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5)
Description: Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.
Study NCT04941755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days
Study NCT05681377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: After cessation of remimazolam infusion, flumazenil 0.2 mg is administered intravenously over 15 seconds. If consciousness is not adequately restored within 3-5 minutes, a second dose of 0.1 mg intravenously over 15 seconds is administered. If necessary, 0.1 mg may be administered repeatedly at 3-5 minute intervals, and the maximum dose of 1 mg should not be exceeded.
Study NCT05585619 — intervention group
Intervention type: OTHER
Intervention: Pain treatment
Description: Any pain treatment to include medications, procedures, or referrals
Study NCT06319391 — intervention group
Intervention type: OTHER
Intervention: CYP3A5*1*、CYP3A5*1*3
Description: 2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system. After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
Study NCT06319391 — intervention group
Intervention type: OTHER
Intervention: CYP3A5*3*3
Description: 2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system.After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
Study NCT05450666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobility exercises
Description: Before starting the exercise program, a video and exercise program including the importance of shoulder mobilization and stabilization and the knowledge of how to contract the right muscle groups will be shared in order to raise awareness of the athletes. Following the evaluations, in addition to the classical training programs, the athletes will perform the Wall Angels and Anterior Shoulder Stretch, Shoulder Circle Rotation, Prone Shoulder Controlled Articular Rotations and Shoulder Side Stretch exercises, Prone I, T, W, Y's 3 days a week for 8 weeks, accompanied by the same physiotherapist.
Study NCT06006520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: No exercises will be given.
Study NCT06006520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oro-granary exercises.
Description: soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises
Study NCT06006520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercises
Description: We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; It includes activities such as walking, cycling, jogging, aerobic dancing, swimming.
Study NCT06357533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Datopotamab Deruxtecan IV (intravenous)
Study NCT06357533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig IV (intravenous)
Study NCT06357533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab IV (intravenous)
Study NCT06139081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen delivery mode
Description: After the implantation of the mirror, nasal catheter was used to give oxygen through the mouth
Study NCT05924919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole-body Passive Heat Therapy (HT)
Description: The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.
Study NCT05924919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermoneutral Control (CON)
Description: Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
Study NCT04625647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO
Study NCT06472219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 30 mg
Description: This is a glucocorticoid like cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic and vasoconstrictive effects. It binds to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. It has a short duration of action as the half-life is 2.1-3.5 hours and 98% is eliminated in urine. On 21 June 1955 it was granted FDA approval.
Study NCT06472219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This a tablet identical to prednisolone.
Study NCT06516588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Dirrect Current Stimulation
Description: tDCS will deliver direct current through rubber electrodes in saline-soaked sponges. Device sends a low-level current from the positive electrode, the anode, to the negative electrode, the cathode. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10mA. The anode will be placed over the LDLPFC and the cathode over the contralateral supra-orbital area.
Study NCT06516588 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Dirrect Current Stimulation
Description: tDCS will deliver direct current through rubber electrodes in saline-soaked sponges. Device sends a low-level current from the positive electrode, the anode, to the negative electrode, the cathode. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10mA. The anode will be placed over the LDLPFC and the cathode over the contralateral supra-orbital area.
Study NCT05570526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Puritan's Pride ® Melatonin 5mg tablets orally once daily.
Study NCT05570526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.
Study NCT05197010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercise program via a smartphone application
Description: Daily home based exercise program (30min/day, 7days/week for 6 weeks).
Study NCT04596449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study intervention
Description: The sleep structure of healthy volunteers will be recorded (9 Electroencephalograms (EEG), 2 Electrooculograms (EOG), 2 Electromyograms (EMG) and 2 Electrocardiograms (ECG)) during 1 night. The characteristics of the spindle (density, frequency and amplitude) will be automatically analyzed from purified EEG during Non Rapid Eye Movement sleep (NREM).~Volunteers will completed a neuropsychological evaluation that will evaluate Sustained attention (simple reaction time test), Vigilance (TAP Vigilance), Sustained and selective attention (CPT II), Inhibition (Stroop test), Mental flexibility (TAP flexibility) , Executive operation (Tower of London), Short-term memory (Wechsler code test).~Driving performance will be analyzed as part of a complex scenario involving attentional and high-level functions on a driving simulator.
Study NCT05178589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One Unit TENS
Description: TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Single unit TENS was administered via 2 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
Study NCT05178589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two Unit TENS
Description: TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Double unit TENS was administered via 4 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
Study NCT05621200 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial stimulation over the cerebellar hemispheres
Description: Single session of Transcranial stimulation over the cerebellar hemispheres
Study NCT05621200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial stimulation over the cerebellar hemispheres
Description: Single session of Transcranial stimulation over the cerebellar hemispheres
Study NCT05388188 — intervention group
Intervention type: DRUG
Intervention: sublingual sufentanil
Description: Dsuvia in patients with SCD VOC as a bridging medication.
Study NCT06232356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mobile Web App
Description: all participants will undergo an assessment of respiratory health by analyzing the sound of exhaled air recorded by the participant's mobile phone
Study NCT06392737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-AI guided cognitive prostate targeted biopsy
Description: Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
Study NCT06392737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine cognitive prostate targeted biopsy
Description: Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
Study NCT04860635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F14 (sustained release celecoxib)
Description: Celecoxib in BEPO® drug delivery system
Study NCT04523142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyclASol Ophthalmic Solution
Description: Cyclosporine A solution in vehicle
Study NCT06049667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTQ2494 tablet
Description: Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle).
Study NCT04911920 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Patient Rated Tennis Elbow Evaluation
Description: Participants are asked to complete questionnaires at three measurement time points.
Study NCT06775860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-332 Tablets
Description: ICP-332 will be administered as tablet
Study NCT06775860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICP-332 Placebo Tablets
Description: ICP-332 Placebo will be administered as tablet
Study NCT04737668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intrathecal pump refill with Virtual Reality
Description: VR game
Study NCT04737668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intrathecal pump refill with distraction
Description: Video
Study NCT04737668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intrathecal pump refill
Description: daily routine care for pump refill
Study NCT05750225 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: 12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
Study NCT05750225 — intervention group
Intervention type: OTHER
Intervention: Patient satisfaction questionnare
Description: VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
Study NCT04744896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryolipolysis(3 max cool shaping)
Description: cryolioplysis applied over abdomen area
Study NCT04744896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryolipolysis(3 max cool shaping)
Description: cryolioplysis applied over abdomen area
Study NCT04744896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill (jkexer focus 8020A)
Description: aerobic training ( high intensity interval training)
Study NCT04744896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill (jkexer focus 8020A)
Description: aerobic training ( high intensity interval training)
Study NCT05045794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaSmart Liver Machine Perfusion System
Description: Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.
Study NCT05045794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static cold storage
Description: Donor liver retrieval and preservation using standard of care cold storage methods
Study NCT05045794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Static cold storage
Description: Donor liver retrieval and preservation using standard of care cold storage methods
Study NCT04339088 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires to assess quality of life